Brivaracetam

From Ganfyd

Jump to: navigation, search

Contents

Introduction

Brivaracetam has been developed to have less interactions and be more specific in partial and generalized seizures[1]Its relatively favourable profile in animal models of memory[2]is likely to result in comparative trials in neurodegenerative conditions associated with secondary epilepsy.

Clinical Use

Indications

60px-Flag of EU.png
  • Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy

Administration

  • Oral adult dose typically 50-100mg a day, up to 200mg/day
  • iv

Clinical Issues

Contra-indications

Cautions and Interactions

Side effects

  • Fatigue
  • Dizziness
  • Somnolence (> 14%)

Special advice

Pharmacology

There are four stereoisomers[3]. It is a high-affinity ligand of the synaptic vesicle protein 2A, and 10-30 fold more potent than levetiracetam. However it does not share levetiracetam's inhibitory activity on the high voltage Ca2+ channels and AMPA receptors. Brivaracetam may act as a partial antagonist on neuronal voltage-gated sodium channels.

References

Personal tools